GLP-1s appear to cut cancer risk. Researchers are asking why and how : NPR

Key Points:

• Recent studies suggest GLP-1 obesity treatments may reduce cancer risk by reversing obesity-related carcinogenic risks and potentially suppressing tumors through anti-inflammatory effects.
• Research presented at the American Society of Clinical Oncology meeting showed GLP-1 drugs lowered risks in six out of seven cancers, with significant reductions in breast, liver, colorectal, and non-small cell lung cancers.
• The observed cancer risk reductions extend beyond obesity-related cancers, indicating broader potential benefits of GLP-1 drugs, originally developed for diabetes and now used for obesity and other metabolic conditions.
• Experts caution the current evidence is correlational and derived from retrospective data lacking detailed patient lifestyle information, so definitive conclusions on GLP-1s as cancer treatments are premature.
• New clinical trials are underway to investigate how GLP-1 drugs affect inflammation, immune response, and cancer markers, with researchers closely monitoring patients to better understand these mechanisms.